| Literature DB >> 32650191 |
Jenna van Draanen1, Christie Tsang2, Sanjana Mitra3, Mohammad Karamouzian4, Lindsey Richardson5.
Abstract
BACKGROUND: Socioeconomic marginalization (SEM) is an important but under-explored determinant of opioid overdose with important implications for health equity and associated public policy initiatives. This systematic review synthesizes evidence on the role of SEM in both fatal and non-fatal overdose among people who use opioids.Entities:
Keywords: Drug-related death; Poisoning; Poverty; Socioeconomic status; Toxicity
Year: 2020 PMID: 32650191 PMCID: PMC7313902 DOI: 10.1016/j.drugalcdep.2020.108127
Source DB: PubMed Journal: Drug Alcohol Depend ISSN: 0376-8716 Impact factor: 4.492
Systematic Review Search Strategy and PICOS Criteria.
| Search Concepts* | SEM: Social class, socioeconomic status; low education; unemployment, labour market exclusion; material insecurity, material hardship; housing insecurity, homelessness, unstable housing; hunger, food insecurity; health care access, social service access; poverty and income inadequacy; social assistance, income assistance, welfare, disability; prohibited income generation (e.g. theft, drug dealing, street-based work); early childhood development; incarceration, criminal justice system involvement; persistent disadvantage, vulnerability, stigma, social isolation, social exclusion, marginalization; service barriers and availability, location of social services, health care service availability and accessibility; housing availability, housing affordability; urbanization, neighborhood disorder; disparities, income inequality, wealth inequality, neighborhood median income; synchronized social assistance, (“cheque day effect” or “check effect”); welfare, disability, and income assistance policies; criminal justice and drug policies. |
| Databases | MEDLINE (Ovid), Embase (Ovid), PsycINFO (EBSCOhost), CINAHL (EBSCOhost), Google Scholar, Cochrane Central Registry of Controlled Trials (CENTRAL), and Cochrane Drug and Alcohol Group (CDAG) Specialized Registry |
| Other Search Strategies | In addition to searching electronic databases, additional searches on clinicaltrials.gov, a comprehensive grey literature search (e.g., |
| PICOS Criteria | Population: People who use opioids in North America, Europe, the United Kingdom, Australia, and New Zealand. Articles were only included if they had opioids identified as a cause of overdose. Poly drug-related overdose papers were included if they included opioid overdose in the cases. |
Notes: *Terms related to these key concepts were entered into all computer databases, combined using appropriate Boolean operators. All terms were searched both as subject headings as well as key words. See Appendix A for a summary of the Medline search terms included.
Fig. 1PRISMA Flow Diagram.
Summary of Measures and Findings for Included Studies.
| Author (Year) | Measure of SEM | Opioids involved | Overdose characteristic | Measure of overdose | Main findings | Risk of bias |
|---|---|---|---|---|---|---|
| SES composite | Prescription & non-prescription | Intentional & unintentional; fatal | ICD-10 codes for opioid poisoning deaths | Socioeconomic Status: Three clusters were created from a two-step cluster analysis: | Poor | |
| Criminal justice involvement | Prescription & non-prescription | NR; fatal | ICD-10 codes for opioid poisoning deaths | Recent release from prison: | Fair | |
| Employment, SES composite, Criminal justice involvement | NR | Unintentional; fatal | Opioid overdose deaths identified through Office of the Medical Examiner (OME) | Unemployment rate: | Fair | |
| SES composite: Including percent of persons per precinct who had less than a high school education, earned less money annually than 200 % of the federal poverty level, and received public assistance, as well as the percent of households per precinct | ||||||
| Misdemeanor arrest rate (per 1000): | ||||||
| Criminal justice involvement | Non-prescription | NR; fatal | Opioid overdose deaths identified through OME | Incarceration in year preceding death: | Poor | |
| Employment, Social support, | Non-prescription | NR; non-fatal | Self-reported lifetime history of overdose | Relationship dissatisfaction: | Poor | |
| Homelessness & Housing, | Prescription & non-prescription | Unintentional & undetermined; fatal | ICD-10 codes for opioid poisoning deaths | Median house price: | Fair | |
| Median household income: | ||||||
| No significant associations were found between median household income, unemployment rate, proportion of the population with health insurance and opioid and prescription opioid overdose death. | ||||||
| SES composite | Prescription | NR; fatal & non-fatal | ICD-9 codes for non-fatal opioid poisonings & State death certificates | Neighborhood Deprivation Index: Neighborhood deprivation index was created based on home address and census tract variables (e.g. households in poverty) from the U.S. Census Bureau's 2006–2010 American Community Survey. No further information on how the index was created is provided. | Fair | |
| Criminal justice involvement, SES composite, Education, Employment, Social support | NR | NR; non-fatal | Self-reported lifetime history of non-fatal opioid overdose | Jail sentences over 6 months: | Poor | |
| Area-level deprivation: Using residential postal codes, area-level deprivation score was calculated based on the Italian deprivation index at census block level. Five indicators (low level of education, unemployment, nonhome ownership, one parent | ||||||
| No significant associations were found between compulsory education, unemployment, family situation and overdose death. | ||||||
| Income and poverty, | Prescription & non-prescription | Unintentional; fatal | Post-mortem toxicology and autopsy reports for analgesic opioids and heroin deaths | Higher median income | Fair | |
| Dilapidated Housing Structures: | ||||||
| Family fragmentation (analgesic vs. non-overdose death): | ||||||
| Social support, Education, | Prescription & non-prescription | Unintentional; fatal | Post-mortem toxicology and autopsy reports for deaths with at least one opioid | Marital Status: | Fair | |
| Educational Attainment: | ||||||
| Unemployment (opioid overdose decedents vs. state-level population): | ||||||
| Health insurance | Prescription | NR; fatal & non-fatal | ICD-9 codes for opioid poisoning deaths and hospitalization and ED visits | Medicaid eligibility type: | Good | |
| Health insurance | Prescription | Unintentional; fatal | ICD-10 codes for opioid poisoning deaths | Medicaid enrollment: Rate of deaths attributed to Prescription Opioid OD by Medicaid Status comparing the Medicaid population to anyone not enrolled in Medicaid in Washington; | Fair | |
| Education, | NR | NR; non-fatal | Self-reported lifetime history of non-fatal opioid overdose | Educational Attainment: | Poor | |
| Ethnicity: | ||||||
| No significant associations found between employment status, housing situation, marital status or living situation and overdose in in individuals recently released from prison. | ||||||
| Employment, | Prescription & non-prescription | NR; non-fatal | Self-reported lifetime history of non-fatal opioid overdose | No significant associations were found between employment status, incarceration in the past 30 days, health insurance status, marital status and opioid overdose. | Poor | |
| Income & poverty | Prescription & non-prescription | Intentional & unintentional; fatal & non-fatal | ICD-9 codes for opioid poisoning deaths and hospitalization and ED visits | Median household income: | Fair | |
| Health insurance | Prescription | Unintentional; fatal | ICD-10 codes for opioid poisoning deaths | Medicaid enrollment: Opioid overdose fatality rates, comparing the Medicaid population to anyone not enrolled in Medicaid in Montana; | Fair | |
| Health insurance, Income & poverty | Prescription & non-prescription | Intentional & unintentional; non-fatal | Opioid -related near-fatal events involving mechanical ventilation | Insurance status: | Poor | |
| No significant associations between income quartiles of residence and frequency of ED visits or hospitalizations for non-fatal overdose | ||||||
| Employment | Prescription & non-prescription | Intentional & unintentional; fatal & non-fatal | ICD-10 codes for opioid poisoning deaths | County-level Employment: | Good | |
| Criminal justice involvement, | Prescription & non-prescription | NR; non-fatal | Self-reported heroin overdose in the past year | Incarceration: | Poor | |
| No permanent housing was not associated with non-fatal overdose. | ||||||
| Income & poverty, | Prescription & non-prescription | Intentional & unintentional; fatal | Opioid overdose deaths identified through coroners | Median household income: | Fair | |
| % Higher education: | ||||||
| Criminal justice involvement | Prescription & non-prescription | Unintentional; fatal | Post-mortem reports for deaths with at controlled drugs | Incarceration with heroin-related death: | Fair | |
| Health insurance, | Prescription & non-prescription | Intentional & unintentional; fatal & non-fatal | ICD-9 codes for opioid poisoning deaths and hospitalization and ED visits | Insurance Status and Poverty: | Fair | |
| Social support | Prescription | NR; non-fatal | Post-overdose reports for overdose with prescription opioids | Marital Status: | Fair | |
| Criminal justice involvement, | Non-prescription | NR; non-fatal | Self-reported on a scale of 1−10 | Incarceration and Recent overdose: | Poor | |
| Sex Work: | ||||||
| Homelessness: | ||||||
| Criminal Justice Involvement | NR | NR; fatal | ICD-8,910 codes for opioid poisoning deaths | Incarceration: | Fair | |
| Employment, | Prescription | Intentional & unintentional; fatal | ICD-10 codes for opioid poisoning deaths | Unemployment Rate: | Fair | |
| Educational Attainment: Educational attainment was associated with a decrease of 0.08 opioid-related overdose deaths per 100,000 population annually | ||||||
| Social support, | Prescription | Unintentional; fatal | ICD-10 codes for opioid poisoning deaths | Marital Status and College Education: The methadone group had fewer people who were married ( | Fair | |
| Income & Poverty, | Prescription | NR; non-fatal | ICD-9 codes for opioid-related poisoning | Median Household Income: | Good | |
| Indigenous ancestry: | ||||||
| SES composite, | Prescription | Intentional & unintentional; fatal | Post-mortem toxicology and autopsy reports for opioid-related deaths | Socioeconomic Status: Socioeconomic status using residential address and the Victorian Index of Relative Socioeconomic Disadvantage. Lower scores/quintiles indicate an area has many people with low levels of education, employed in low-skill jobs, and many households with low income. | Fair | |
| Employment status: No association between unemployed and on other government benefits versus all other employment status types with fatal drug toxicity cases involving oxycodone (2003−2009) | ||||||
| Homelessness & housing, | NP | NR; non-fatal | Self-reported history of overdose | Currently Homeless: | Poor | |
| Social Support | Prescription & non-prescription | Unintentional; fatal | Post-mortem toxicology and autopsy reports for opioid-related deaths | Marital Status: | Fair | |
| Health insurance | Prescription & non-prescription | NR; fatal | ICD-10 codes for opioid poisoning deaths | Medicaid Status: | Fair | |
| Homelessness & housing, | NR | NR; non-fatal | Self-reported history of overdose | Homelessness: | Poor | |
| No significant association between education/recent incarceration/employment and overdose | ||||||
| Education, | Prescription & non-prescription | Unintentional; fatal | ICD-10 codes for opioid poisoning deaths | Education: | Good | |
| No significant association between neighborhood poverty and unintentional opioid overdose | ||||||
| Income & poverty | Prescription & non-prescription | Unintentional; fatal | Post-mortem toxicology and autopsy reports for opioid-related deaths | Poverty: | Fair | |
| Homelessness & housing | Prescription & non-prescription | NR; non-fatal | Self-reported history of overdose | Homelessness: | Poor | |
| Criminal justice measures: | ||||||
| Income & poverty | Prescription & non-prescription | NR; non-fatal | Post-overdose reports for opioid-related ODs | Income Assistance: | Fair |
Statistically significant results denoted in bold.
Study Design and Sample Characteristics of Included Studies.
| First Author (Year) | Study design/ Location | Sample characteristics | Ethnicity | Recruitment and data source |
|---|---|---|---|---|
| Cross-sectional/ Norway | N: 1628 | NR | - Norwegian Cause of Death Registry (2003–2009) | |
| Cohort/ USA | N: 30,237; | White, non-Hispanic: 62 %; Black, non-Hispanic: 20 %; Hispanic: 13 %; | - Washington State Department of Corrections (1999–2003) | |
| Longitudinal data/ USA | *N: 74 police precincts; Age: Mean percent under 35 (SD): 51.2 % (7.5); | *Black: Mean percent (SD): 27.5 % (27.2) | - Office of the Chief Medical Examiner data in New York | |
| Cross-sectional/ USA | N: 530; | White: 90.2 %;Non-white: 9.8 % | - Rhode Island Office of Medical Examiner Data | |
| Cross-sectional/ Australia | N: 163; | NR | - Survey with young people (15–30 years) who used heroin from three inner-metropolitan Melbourne general practices (June - December 2000) | |
| Longitudinal data/ USA | N: 50 states; | NR | - CDC’s Detailed Mortality File (1999−2014) | |
| Cohort/ USA | N: 396,452; | Hispanic: 17.2 %; Asian: 9.7 %; Black: 9.4 %; Multi-racial: 4.5 %; | - Kaiser Permanente Northern California Electronic Health Records database (2011−2014) | |
| Cross-sectional/ Italy | N: 265; | NR | - Therapeutic community program participants | |
| Case control/ USA | N: 6413; Age:15−44 :58.9%,45−64: 41.1 %, | White: 39.6 %; Black: 25.7 %; Hispanic: 29.7 % | - Office of the Chief Medical Examiner New York (2000−2006) | |
| Cross-sectional/ USA | N: 254; | White: 98.3 %; Black: 0.4 %; Other: 0.8 | - Prescription Pain Medication Dataset from the Utah Department of Health (2008−2009) | |
| Cohort/ USA | N: 297,634; | White: 56.2 %; Black: 28.2 %; Hispanic: 12.1 %; Other: 3.6 % | - Medicaid records from Pennsylvania Department of Human Services (2010−2012) | |
| Cross sectional/ USA | N: 1668 | NR | - Washington State Department of Health (2004−2007) | |
| Cross-sectional/ USA | N: 478; | White: 44.4 %; Black: 52.9 %; Other: 2.7 % | - Survey with criminal justice involved individuals who reported to a community corrections office for drug monitoring (2012) | |
| Cross-sectional/ USA | N: 345; Age: 29.1 % older than 50 years; | Caucasian: 60.0 %; Hispanic: 3.5 | - Survey with methadone maintenance clinic and syringe program participants | |
| Cross-sectional/ USA | N: 9647; Age: -20 | Non-Hispanic White: 73.9 %; | - Nevada State inpatient and emergency department databases (2011−2013) | |
| Cohort/ USA | N: 358; | White: 84.1 %; Other:15.9 % | - Montana’s Office for Vital Records and Montana Medicaid enrolment records (2003−2012) | |
| Cohort/ USA | N: 19,709; | Non-Hispanic White: 69 %; | - California and Florida State Emergency Department Databases and State Inpatient Databases (2010−2011) | |
| Longitudinal data/ USA | N: 3138 counties; | NR | - State Emergency Department Databases | |
| Cross-sectional/ USA | N: 443; | White: 73 %; African-American: 8%; Native American, Alaska Native: 5%; Native Hawaiian, Pacific Islander: 1%; Asian, South Asian: 1%; Latino, Hispanic: 6%; Multi-racial: 6% | - Surveys for individuals using syringe exchange sites in King County and Seattle, Washington | |
| Ecological/ USA | N: 1065; | Hispanic: 12 %;White: 84 %;Asian: 2.4 %;Black: 1.7 % | -Orange County Coroner Division’s data file (2010−2014) | |
| Cross-sectional/ United Kingdom | N: 291; | NR | -Drug-related death monitoring data from two Scottish National Health Service Board areas (2006−2007) | |
| Cross sectional/ USA | N: 1540 | Black: 12.7 %;White: 77.2 %;Other: 5.1 % | -Wisconsin Division of Public Health’s emergency department visit and hospital discharge datasets (2003–2012) | |
| Nested case-control/ USA | N: 45,153; | Non-Hispanic White: 56.8 %; | -PharMetrics Plus data set from the IMS Health Real-World Data Adjudicated Claims–US Database | |
| Cross-sectional/ USA | N: 795 | Caucasian: 80.4 %; | - Survey with participants were who were <30 years old and had injected once or more in the prior month recruited using street outreach and snowball techniques | |
| Cohort/ Norway | N: 338 | NR | - Survey with participants receiving treatment at the State Clinic for Drug Addicts (1981−1991) | |
| Interrupted time-series/ USA | N: 343−34 (states) | NR | -State prescription drug monitoring programs (<2011) | |
| Cross-sectional/ USA | N: Methadone (n = 87) | NR | - Coroner’s data from West Virginia (2006) | |
| Longitudinal data/ USA | N: 5513 | NR | -Nebraska and South Dakota inpatient hospital discharges (2007−2012) | |
| Cohort/Australia | N: 172 | NR | -National Coroners Information System (NCIS) Victorian Drugs Module (VDM; 2003) | |
| Cross-sectional/ USA | N: 1427 | Black: 51.3 %;White: 35.2 %;Latino: 7.3 %; | -Survey with street recruited people who inject drugs in San Francisco Bay Area, California | |
| Longitudinal data/ USA | N: 1120 | White, non-Hispanic: 42.0 %; Hispanic: 52.5 %; | -Office of the Medical Investigator and the Toxicology Bureau of the Scientific Laboratory Division, New Mexico Department of Health (1998−2002) | |
| Longitudinal data/ USA | N: NR | NR | -New York state vital statistics multiple-cause-of-death data | |
| Cohort/ USA | N: NR | Race in group experienced OD: | -Survey with young people who use drugs in the Risk Evaluation and Assessment of Community Health III (REACH III) cohort (1999−2002) | |
| Cross-sectional/ USA | N: 2649 | Non-Hispanic Black: 21.6 %; | - NYC linked death certificates and medical examiner files (2005−2010) | |
| Cross-sectional/ USA | N: 331 | Non-Hispanic White: 71.0 %; | -California Electronic Death Reporting System (2010−2012) | |
| Cross-sectional/ USA | N: 573 | White: 50.1 %; | -Survey with people who inject drugs in San Diego, California | |
| Cross-sectional/ Canada | N: 1338 | NR | - Insite facility’s on-site surveillance database |
*Aggregate data collected at police precinct level.
Summary of Risk of Bias Assessments for Included Studies. (For interpretation of the references to colour in this table, the reader is referred to the web version of this article.)
Notes: Y = yes, N = no, CD = cannot determine, NR = not reported, N/A = not applicable.
*Domains 1–14 for Studies Assessed with the Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies).
D1. Was the research question or objective in this paper clearly stated?
D2. Was the study population clearly specified and defined?
D3. Was the participation rate of eligible persons at least 50 %?
D4. Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants?
D5. Was a sample size justification, power description, or variance and effect estimates provided?
D6. For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured?
D7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed?
D8. For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)?
D9. Were the exposure measures clearly defined, valid, reliable, and implemented consistently across all study participants?
D10. Was the exposure(s) assessed more than once over time?
D11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants?
D12. Were the outcome assessors blinded to the exposure status of participants?
D13. Was loss to follow-up after baseline 20 % or less?
D14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)?
^Domains 1–12 for Studies Assessed with the Quality Assessment Tool for Case Control Studies.
D1. Was the research question or objective in this paper clearly stated and appropriate?
D2. Was the study population clearly specified and defined?
D3. Did the authors include a sample size justification?
D4. Were controls selected or recruited from the same or similar population that gave rise to the cases (including the same timeframe)?
D5. Were the definitions, inclusion and exclusion criteria, algorithms or processes used to identify or select cases and controls valid, reliable, and implemented consistently across all study participants?
D6. Were the cases clearly defined and differentiated from controls?
D7. If less than 100 percent of eligible cases and/or controls were selected for the study, were the cases and/or controls randomly selected from those eligible?
D8. Was there use of concurrent controls?
D9. Were the investigators able to confirm that the exposure/risk occurred prior to the development of the condition or event that defined a participant as a case?
D10. Were the measures of exposure/risk clearly defined, valid, reliable, and implemented consistently (including the same time period) across all study participants?
D11. Were the assessors of exposure/risk blinded to the case or control status of participants?
D12. Were key potential confounding variables measured and adjusted statistically in the analyses? If matching was used, did the investigators account for matching during study analysis?
Fig. 2Aggregate Risk of Bias Plot for Observational Cohort and Cross-Sectional Studies.